Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- IQVIAIQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest GroupCompanies: IQVIA Holdings, Inc.Everest GroupRESEARCH TRIANGLE PARK, N.C., August 17, 2026--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group’s "Top 50™ Pharmaceutical Technology Providers" report for 2026.
- AbbottAbbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcareCompanies: Abbott LaboratoriesThe NACHC and Abbott Food for Health Initiative is a multi-year "food is medicine" effort to support the integration of nutrition as a foundational component of primary care provided by Community Health Centers (CHCs) across the country Certification program alongside training and...
- Investigation Alert: NYSE: HIMS: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the FirmKessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or acquired Hims & Hers Health, Inc. securities and experienced significant financial losses.
- Kaplan Fox & Kilsheimer LLPKaplan Fox is Investigating Hims & Hers Health, Inc. (HIMS) and Encourages Investors Who Suffered Losses to Contact the FirmKaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing...
- Radiation Detection CompanyRadiation Detection Company Introduces Radiant, Expanding Real-Time Radiation Safety for High-Exposure Clinical EnvironmentsGEORGETOWN, Texas, August 17, 2026--Radiation Detection Company (RDC), the world's longest-operating providers of occupational dosimetry services, today announced the launch of Radiant real-time dosimetry, a connected electronic dosimetry solution designed to provide clinicians with immediate visibility into radiation levels during high-exposure medical procedures.
- Go dēhp® and dēhp® Theraputic Sponsor the 2026 Southwestern School for Behavioral Health Studies Conference and Present Proprietary Dehp® High Treatment to AttendeesPHOENIX, August 17, 2026--Go dēhp® and dēhp® Theraputic invite health care professionals attending the 58th Annual Southwestern School for Behavioral Health Studies Conference to attend a special session on their proprietary Dehp® High Treatment. Taking place at Gila River Resorts & Casinos – Wild Horse Pass in Chandler, Arizona, the conference is sponsored by Go dēhp® and dēhp® Theraputic, The Dehp® High Treatment session will be presented by Go dēhp® and dēhp® Theraputic CEO Josette Sullins an
- Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of DirectorsCocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.
- The Global Vitiligo FoundationGlobal Vitiligo Foundation Applauds Incyte’s "Moments of Clarity" Campaign for Elevating Patient Voices and Advancing Vitiligo AwarenessCompanies: IncyteMECHANICSBURG, Pa., August 17, 2026--The Global Vitiligo Foundation (GVF) proudly recognizes and supports Incyte’s Moments of Clarity campaign, a powerful storytelling initiative that highlights the lived experiences of individuals with nonsegmental vitiligo. Through authentic patient narratives, the campaign closely aligns with GVF’s mission to improve the quality of life for people affected by vitiligo through education, advocacy, and community connection.
- AARD INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Aardvark Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the FirmA shareholder class action lawsuit has been filed against Aardvark Therapeutics, Inc. (“Aardvark”) (NASDAQ: AARD). The lawsuit alleges that Defendants, in Aardvark’s Registration Statement and throughout the Class Period, made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (i) ARD-101 was less safe than Defendants had led investors to believe; and (ii) accordingly, ARD-101’s clinical, regulatory, and commercial prospects were overstated.
- Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)Company announcement No. 40 / 2026
- Jeff Social MarketingMindSeed Expands Access to Specialized Virtual Therapy Across OntarioMindSeed is highlighting its virtual model of mental health care, providing clients across Ontario with access to a centre of clinical excellence without requiring them to travel to a physical clinic.The MindSeed teamTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/11862/309771_d3f06c0804631ad1_001full.jpgBased in Toronto, MindSeed provides virtual therapy to clients across Ontario through a...
- Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced the grant of inducement equity awards outside of the Company's stockholder-approved equity compensation plans to Leonardo Nicacio in connection with his commencement of employment as Chief Medical Officer of the Company. The grants were approved by the Compensation Committee of the Board of Directors effective as of August 16, 2026, as inducements material to Mr. Nicacio entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).